Holen Sie sich die Stockscreener-App
16.21
37.94%
-9.91
Handel nachbörslich:
16.01
-0.20
-1.23%
Schlusskurs vom Vortag:
$26.12
Offen:
$16
24-Stunden-Volumen:
5.73M
Relative Volume:
8.59
Marktkapitalisierung:
$656.35M
Einnahmen:
$128.29M
Nettoeinkommen (Verlust:
$-30.69M
KGV:
-19.77
EPS:
-0.82
Netto-Cashflow:
$-27.17M
1W Leistung:
-39.22%
1M Leistung:
-39.81%
6M Leistung:
-66.12%
1J Leistung:
-68.36%
1-Tages-Spanne:
$14.37
$16.51
1-Wochen-Bereich:
$14.37
$26.81
52-Wochen-Spanne:
$14.37
$66.54
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Vergleichen Sie RXST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
16.21 | 656.35M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
131.63 | 228.29B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
98.50 | 145.69B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
368.15 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.89 | 112.70B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.98 | 42.75B | 5.72B | 4.17B | 259.90M | 6.97 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) - Seeking Alpha
JPMorgan cuts RxSight stock rating, slashes price target to $17 - Investing.com India
RxSight downgraded to Underweight from Overweight at JPMorgan - TipRanks
JPMorgan Double Downgrades RxSight Inc. (RXST) to Underweight - StreetInsider
Rxsight adjusts 2025 revenue guidance to $160M-$175M amid premium IOL market challenges - MSN
RxSight Analyst Flags Growth Slowdown As Revised Outlook Misses Expectations - Benzinga
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of Americ - GuruFocus
RxSight stock tumbles on lowered 2025 guidance By Investing.com - Investing.com UK
RxSight stock tumbles on lowered 2025 guidance - Investing.com
BTIG cuts RxSight stock price target to $28 from $44 - Investing.com
RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says - MarketScreener
RxSight Faces Market Challenges As Revenue Guidance Drops - Finimize
RxSight Inc. (RXST) PT Lowered to $28 at BTIG - StreetInsider
BofA cuts RxSight stock rating, price target to $22 from $36 - Investing.com
Stifel maintains RxSight stock hold, price target at $28 - Investing.com
RxSight plunges after guidance cut; BofA downgrades - MSN
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips - Investing.com
RxSight stock down after guidance cut (update) (RXST:NASDAQ) - Seeking Alpha
Sector Update: Health Care - MarketScreener
RxSight’s Growth Potential Amid Challenges: A Buy Recommendation by David Saxon - TipRanks
RxSight’s Long-Term Growth Potential Justifies Buy Rating Despite Short-Term Challenges - TipRanks
RxSight’s Undervaluation and Growth Potential Justify Buy Rating Despite Revenue Shortfall - TipRanks
RxSight double downgraded to Underperform at BofA after FY25 guidance cut - TipRanks
Needham maintains Buy on RxSight stock, price target at $43 - Investing.com India
BofA Securities Downgrades RxSight Inc. (RXST) to Underperform - StreetInsider
RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges - Yahoo Finance
Needham Reiterates Buy Rating on RxSight Inc. (RXST) - StreetInsider
HighTower Advisors LLC Lowers Position in RxSight, Inc. (NASDAQ:RXST) - Defense World
RxSight Preliminary Q1 Revenue Increases; Lowers 2025 Revenue Guidance - MarketScreener
RxSight, Inc. Provides Revenue Guidance for the First Quarter 2025 - MarketScreener
RxSight sees Q1 revenue $37.9M, consensus $47.0M - TipRanks
RxSight Expects 28% Growth In Q1 Revenue; Cuts FY25 Revenue Outlook - Nasdaq
RxSight Cuts 2025 Revenue Target by $25M Despite Strong Lens Sales Growth - Stock Titan
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance - Bluefield Daily Telegraph
(RXST) Trading Report - news.stocktradersdaily.com
RxSight, Inc. (NASDAQ:RXST) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
BofA sees Bausch + Lomb IOL recall news as positive for RxSight - MSN
Midday Stock Roundup: Boot Barn, Beta Bionics down - Orange County Business Journal
RxSight Gains Competitive Edge with Market Shifts and Expansion Opportunities - TipRanks
RxSight, Inc. (NASDAQ:RXST) Shares Bought by Swiss National Bank - Defense World
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Jefferies starts coverage on Rxsight with 'buy' on growth potential - TradingView
RxSight, Inc. (NASDAQ:RXST) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of America Issues Pessimistic Forecast for RxSight (NASDAQ:RXST) Stock Price - Defense World
Where are the Opportunities in (RXST) - news.stocktradersdaily.com
BofA cuts RxSight stock price target to $36, maintains Buy rating - Investing.com Canada
RxSight price target lowered to $36 from $60 at BofA - TipRanks
RxSight’s Path to Profitability: A Buy Rating Amid Revenue Growth and Operational Leverage - TipRanks
BofA cuts RxSight stock price target to $36, maintains Buy rating By Investing.com - Investing.com South Africa
RxSight Inc. (RXST) PT Lowered to $36 at BofA Securities - StreetInsider.com
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.71%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):